April 28, 2021
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F. Street, NE
Washington, D.C. 20549
Attention: Deana Virginio
Re: | NeuroBo Pharmaceuticals, Inc. |
| Registration Statement on Form S-3 |
| File No. 333-255418 |
| Acceleration Request |
| Requested Date: | April 30, 2021 |
| Requested Time: | 4:01 P.M. Eastern Time |
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, NeuroBo Pharmaceuticals, Inc. (the “Company”) hereby respectfully requests that the above-referenced Registration Statement on Form S-3 (File No. 333-255418) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above, or as soon as practicable thereafter, or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. The Company hereby authorizes each of Phillip D. Torrence, Jeff Kuras and Patrick Valenti of Honigman LLP, counsel to the Company, to make such request on its behalf.
Please confirm the effectiveness of the Registration Statement with Phillip D. Torrence of Honigman LLP by telephone at 269.337.7702, Jeff Kuras of Honigman LLP by telephone at 313.465.7446 or Patrick Valenti of Honigman LLP by telephone at 313.465.7985.
| Sincerely, | ||
| | ||
| NEUROBO PHARMACEUTICALS, INC. | ||
| | ||
| | ||
| By: | /s/ Richard Kang | |
| Name: Richard Kang, Ph.D. | ||
| Title: CEO and President | ||
cc: | Phillip D. Torrence, Honigman LLP |
| Jeff Kuras, Honigman LLP |
| Patrick Valenti, Honigman LLP |